No Data
Lianhuan Pharma Gets Good Manufacturing Practice Certificates for Three Products
Jiangsu Lianhuan Pharmaceutical (600513.SH): received the Pharmaceutical GMP compliance inspection results.
On December 23, according to Gelonghui, Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that it received the "Drug GMP Compliance Inspection Result Notification" from the Jiangsu Provincial Drug Administration website. The scope of inspection includes: Active Pharmaceutical Ingredient [sacubitril/valsartan sodium, Workshop 2, C7-H1 production line (hydrogenation), C5-H1 production line (esterification), C5-H2 production line (acylation), No. 8 fine package (co-crystal)]; Oral solution [Workshop 3, Production line 2 (oral solution)]; Tablets [antitumor drugs, Workshop 3, Tablet (antitumor) production line]. According to the "Drug Administration Law" and "Drug Production Supervision Management"
China Approves Jiangsu Lianhuan Pharmaceutical's Heart Failure Treatment Injection
Jiangsu Lianhuan Pharmaceutical (600513.SH): Digoxin injection obtained pharmaceutical registration certificate.
On December 2, GELONGHUI reported that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that it recently received the 'Pharmaceutical Registration Certificate' approved and issued by the National Medical Products Administration, with the pharmaceutical name: Digoxin Injection. Digoxin Injection can be used to treat adults with mild to moderate heart failure, increase myocardial contractility in pediatric patients with heart failure, and control ventricular rate in patients with atrial fibrillation, atrial flutter with rapid ventricular rates, and supraventricular tachycardia.
Jiangsu Lianhuan Pharmaceutical (600513.SH): Supervisor Wang Chunyuan shareholding 1500 shares.
On November 11, Gelonhui announced that jiangsu lianhuan pharmaceutical (600513.SH) received a notification from the company supervisor, Mr. Wang Chunyuan, who, based on his recognition of the company's long-term investment value, increased his shareholding in the company by a total of 1,500 shares through the secondary market on November 8, 2024, using his own funds.
Improved Earnings Required Before Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHSE:600513) Stock's 28% Jump Looks Justified
Why Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Shaky Earnings Are Just The Beginning Of Its Problems
